Bell2Bell’s latest podcast features Hugh Rogers, CEO and Director of life sciences technology accelerator XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT). During the interview with IBN’s Communications Director Jonathan Keim, Rogers offered an operational update, discussing the company’s most recent achievements and future plans. XPhyto Therapeutics recently obtained European approval and launched an effective 25-minute PCR (polymerase chain reaction) test for COVID-19, with an initial focus on the German market and several other initiatives underway.

This is an exciting time for the company. We’ve taken this product from invention to prototype to validation to commercial approval in about ten months,” Rogers said. He explained that the company’s 25-minute COVID-19 RT-PCR test (Covid-ID Lab) sits between a rapid antigen test and a centralized automated high-throughput PCR, offering diagnostic quality, fast results and ease of administration at point of care, whether that is a medical clinic, a pharmacy, a cruise ship turnover or airport, or any mobile testing center.